DENTSPLY SIRONA’s (XRAY) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of DENTSPLY SIRONA (NASDAQ:XRAY) in a report released on Tuesday morning, Briefing.com Automated Import reports. They currently have a $57.00 price objective on the medical instruments supplier’s stock, up from their prior price objective of $55.00.

Several other equities research analysts have also commented on XRAY. Bank of America initiated coverage on shares of DENTSPLY SIRONA in a research report on Monday, March 18th. They issued a buy rating and a $57.00 price objective on the stock. William Blair reissued an outperform rating on shares of eXp World in a research note on Monday, March 18th. BidaskClub raised shares of Zebra Technologies from a hold rating to a buy rating in a research note on Saturday, July 6th. Wolfe Research initiated coverage on shares of Waters in a research note on Thursday, May 30th. They issued an underperform rating for the company. Finally, UBS Group cut their target price on shares of MEG Energy from C$8.70 to C$6.00 in a research note on Tuesday, March 12th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. DENTSPLY SIRONA presently has an average rating of Buy and a consensus price target of $53.77.

DENTSPLY SIRONA stock opened at $56.77 on Tuesday. DENTSPLY SIRONA has a 52 week low of $33.93 and a 52 week high of $59.40. The company has a quick ratio of 1.35, a current ratio of 2.06 and a debt-to-equity ratio of 0.33. The stock has a 50-day simple moving average of $56.44. The stock has a market cap of $13.40 billion, a price-to-earnings ratio of 28.24, a PEG ratio of 2.13 and a beta of 0.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Friday, May 3rd. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.39 by $0.10. DENTSPLY SIRONA had a negative net margin of 26.48% and a positive return on equity of 8.99%. The business had revenue of $946.20 million for the quarter, compared to analyst estimates of $925.13 million. During the same period in the previous year, the firm earned $0.45 EPS. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. As a group, research analysts forecast that DENTSPLY SIRONA will post 2.35 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 12th. Investors of record on Friday, June 28th will be given a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date is Thursday, June 27th. This is an increase from DENTSPLY SIRONA’s previous quarterly dividend of $0.09. DENTSPLY SIRONA’s dividend payout ratio is 17.41%.

In other news, SVP Daniel P. Key purchased 3,697 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The shares were acquired at an average cost of $54.68 per share, with a total value of $202,151.96. Following the transaction, the senior vice president now owns 9,024 shares in the company, valued at approximately $493,432.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Maureen J. Macinnis sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $56.06, for a total value of $840,900.00. Following the sale, the senior vice president now directly owns 25,360 shares in the company, valued at $1,421,681.60. The disclosure for this sale can be found here. In the last 90 days, insiders acquired 26,417 shares of company stock valued at $1,425,395 and sold 138,922 shares valued at $7,631,805. 0.62% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. Norges Bank acquired a new position in shares of DENTSPLY SIRONA during the fourth quarter valued at $73,734,000. Consulta Ltd bought a new position in DENTSPLY SIRONA during the fourth quarter valued at about $29,768,000. Parnassus Investments CA boosted its stake in DENTSPLY SIRONA by 69.2% during the first quarter. Parnassus Investments CA now owns 1,553,139 shares of the medical instruments supplier’s stock valued at $77,020,000 after buying an additional 635,052 shares in the last quarter. FMR LLC boosted its stake in DENTSPLY SIRONA by 32.7% during the first quarter. FMR LLC now owns 1,616,546 shares of the medical instruments supplier’s stock valued at $80,164,000 after buying an additional 398,372 shares in the last quarter. Finally, Manitou Investment Management Ltd. boosted its stake in DENTSPLY SIRONA by 94.5% during the first quarter. Manitou Investment Management Ltd. now owns 758,274 shares of the medical instruments supplier’s stock valued at $37,603,000 after buying an additional 368,418 shares in the last quarter. 91.66% of the stock is currently owned by institutional investors and hedge funds.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Recommended Story: How is a price target determined?

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.